Zhitong Finance App News, Cinda Biotech (01801) announced that in the third quarter of 2026, the company's business continued to grow strongly, with product revenue exceeding RMB 4.7 billion, an increase of more than 40% over the previous year, fully confirming the strong momentum and continuous implementation of the two-wheel drive strategy. The market penetration of major new products in the integrated pipeline, Xinermei® (Maxilizumab injection), and Cybimin® (tetuyumab N01 injection) continues to increase; various tyrosine kinase inhibitor (TKI) products in the tumor product line have achieved rapid sales growth, which jointly promotes the overall growth of the company's commercial product portfolio. The diverse product matrix collaborates to drive continuous optimization of the revenue structure and richer growth engines.
In 2026, the company will maintain high quality and rapid growth, the industry position of leading innovative domestic biopharmaceutical companies will continue to be consolidated, and the investment value with both certainty and high growth will continue to be demonstrated. In terms of global innovation, the company is promoting three core assets into global phase III clinical development and continuing to expand next-generation innovation pipelines in the fields of oncology, cardiovascular and metabolic (CVM) diseases, autoimmunity, and ophthalmology. Currently, 41 pipelines are in the clinical stage, and more than 100 early-stage R&D projects are progressing in an orderly manner. Global innovation pipeline reserves are scarce, and growth momentum is sufficient. At the same time, the company has more than 20 collaborative R&D projects with multinational pharmaceutical companies such as Pfizer, Eli Lilly, Takeda, and Roche, including five co-development and co-commercialization (Co-Co) pipelines, and its global innovation capabilities continue to receive further international recognition.
The company is currently in a critical period of strategic leap forward, making every effort to advance the transformation journey from a leading local biopharmaceutical company to a world-class biopharmaceutical company. Facing 2030, the company has anchored its core strategic goals: to achieve total revenue of RMB 35 billion to 40 billion yuan, reach the profit margin level of first-class pharmaceutical companies, promote at least five candidates to enter the global multi-center phase III development, and achieve product marketing in major European and American markets. The company will continue to cultivate innovation at the source, accelerate international layout, adhere to high-quality growth, and create long-term sustainable value for patients, shareholders and society.